OBJECTIVE: Many patient-reported outcome (PRO) instruments used in systemic sclerosis (SSc) trials are limited by lack of validation, licensing fees, and complicated scoring systems. We assessed the construct validity for discriminative purposes of 2 new PRO instruments, the Patient-Reported Outcomes Measurement Information System 29-item Health Profile (PROMIS-29) and the Functional Assessment of Chronic Illness Therapy-Dyspnea short form (FACIT-Dyspnea), measuring health status and dyspnea in SSc patients. METHODS: Seventy-three patients participated in a cross-sectional study at a tertiary SSc program. PROMIS-29, FACIT-Dyspnea, and legacy PRO instruments used in clinical trials (Medical Research Council Dyspnea Score, St. George's Respiratory Questionnaire, Health Assessment Questionnaire disability index, and Short Form 36) were administered. Composite severity scores using an adaptation of the Medsger Disease Severity Index were generated using clinical, diagnostic, and laboratory information. PROMIS-29 and FACIT-Dyspnea scores were compared with legacy PRO measures and composite severity scores. RESULTS: The mean patient age (84% women) was 51 years (range 22-72 years). The mean SSc disease duration from the onset of the first non-Raynaud's phenomenon symptom was 7.2 years (range 0-45 years). Spearman's correlation coefficients across FACIT-Dyspnea and PROMIS physical functioning scores with legacy PRO instruments were generally high (range 0.50-0.86); those between PROMIS and FACIT-Dyspnea with composite disease severity scores were more modest, but statistically significant (range 0.33-0.48, P < 0.01). CONCLUSION: PROMIS-29 and FACIT-Dyspnea are valid instruments to measure the health status of SSc patients. PROMIS-29 and FACIT-Dyspnea may be preferable to legacy instruments because they are freely available in multiple languages and simple to administer, score, and interpret.
OBJECTIVE: Many patient-reported outcome (PRO) instruments used in systemic sclerosis (SSc) trials are limited by lack of validation, licensing fees, and complicated scoring systems. We assessed the construct validity for discriminative purposes of 2 new PRO instruments, the Patient-Reported Outcomes Measurement Information System 29-item Health Profile (PROMIS-29) and the Functional Assessment of Chronic Illness Therapy-Dyspnea short form (FACIT-Dyspnea), measuring health status and dyspnea in SSc patients. METHODS: Seventy-three patients participated in a cross-sectional study at a tertiary SSc program. PROMIS-29, FACIT-Dyspnea, and legacy PRO instruments used in clinical trials (Medical Research Council Dyspnea Score, St. George's Respiratory Questionnaire, Health Assessment Questionnaire disability index, and Short Form 36) were administered. Composite severity scores using an adaptation of the Medsger Disease Severity Index were generated using clinical, diagnostic, and laboratory information. PROMIS-29 and FACIT-Dyspnea scores were compared with legacy PRO measures and composite severity scores. RESULTS: The mean patient age (84% women) was 51 years (range 22-72 years). The mean SSc disease duration from the onset of the first non-Raynaud's phenomenon symptom was 7.2 years (range 0-45 years). Spearman's correlation coefficients across FACIT-Dyspnea and PROMIS physical functioning scores with legacy PRO instruments were generally high (range 0.50-0.86); those between PROMIS and FACIT-Dyspnea with composite disease severity scores were more modest, but statistically significant (range 0.33-0.48, P < 0.01). CONCLUSION: PROMIS-29 and FACIT-Dyspnea are valid instruments to measure the health status of SSc patients. PROMIS-29 and FACIT-Dyspnea may be preferable to legacy instruments because they are freely available in multiple languages and simple to administer, score, and interpret.
Authors: E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim Journal: J Rheumatol Date: 1988-02 Impact factor: 4.666
Authors: T A Medsger; A J Silman; V D Steen; C M Black; A Akesson; P A Bacon; C A Harris; S Jablonska; M I Jayson; S A Jimenez; T Krieg; E C Leroy; P J Maddison; M L Russell; R K Schachter; F A Wollheim; H Zacharaie Journal: J Rheumatol Date: 1999-10 Impact factor: 4.666
Authors: Tracy Frech; Ron D Hays; Paul Maranian; Philip J Clements; Daniel E Furst; Dinesh Khanna Journal: Rheumatology (Oxford) Date: 2011-02-15 Impact factor: 7.580
Authors: David T Eton; Diane L Fairclough; David Cella; Susan E Yount; Philip Bonomi; David H Johnson Journal: J Clin Oncol Date: 2003-04-15 Impact factor: 44.544
Authors: Monique E Hinchcliff; Jennifer L Beaumont; Mary A Carns; Sofia Podlusky; Krishna Thavarajah; John Varga; David Cella; Rowland W Chang Journal: J Rheumatol Date: 2014-11-01 Impact factor: 4.666
Authors: Susan E Yount; Jennifer L Beaumont; Shih-Yin Chen; Karen Kaiser; Katy Wortman; David L Van Brunt; Jeffrey Swigris; David Cella Journal: Lung Date: 2016-02-09 Impact factor: 2.584
Authors: Colleen M McCarthy; Jennifer B Hamill; Hyungjin Myra Kim; Ji Qi; Edwin Wilkins; Andrea L Pusic Journal: Ann Surg Oncol Date: 2017-06-13 Impact factor: 5.344
Authors: Vivian M Yeh; Lindsay S Mayberry; Justin M Bachmann; Kenneth A Wallston; Christianne Roumie; Daniel Muñoz; Sunil Kripalani Journal: J Gen Intern Med Date: 2018-12-18 Impact factor: 5.128
Authors: Matthew R Lammi; Robert P Baughman; Surinder S Birring; Anne-Marie Russell; Jay H Ryu; Marybeth Scholand; Oliver Distler; Daphne LeSage; Catherine Sarver; Katerina Antoniou; Kristin B Highland; Otylia Kowal-Bielecka; Joseph A Lasky; Athol U Wells; Lesley Ann Saketkoo Journal: Curr Respir Med Rev Date: 2015
Authors: Felix Fischer; Chris Gibbons; Joël Coste; Jose M Valderas; Matthias Rose; Alain Leplège Journal: Qual Life Res Date: 2018-01-19 Impact factor: 4.147
Authors: Christopher F Thompson; Caroline P E Price; Julia He Huang; Jin-Young Min; Lydia A Suh; Stephanie Shintani-Smith; David B Conley; Robert P Schleimer; Robert C Kern; Bruce K Tan Journal: Int Forum Allergy Rhinol Date: 2015-12-18 Impact factor: 3.858
Authors: Benjamin M Craig; Bryce B Reeve; Paul M Brown; David Cella; Ron D Hays; Joseph Lipscomb; A Simon Pickard; Dennis A Revicki Journal: Value Health Date: 2014-12 Impact factor: 5.725
Authors: Linda Kwakkenbos; Brett D Thombs; Dinesh Khanna; Marie-Eve Carrier; Murray Baron; Daniel E Furst; Karen Gottesman; Frank van den Hoogen; Vanessa L Malcarne; Maureen D Mayes; Luc Mouthon; Warren R Nielson; Serge Poiraudeau; Robert Riggs; Maureen Sauvé; Fredrick Wigley; Marie Hudson; Susan J Bartlett Journal: Rheumatology (Oxford) Date: 2017-08-01 Impact factor: 7.580
Authors: Sofia de Achaval; Michael A Kallen; Maureen D Mayes; Maria A Lopez-Olivo; Maria E Suarez-Almazor Journal: J Rheumatol Date: 2013-06-15 Impact factor: 4.666